Meningiomas are the most common intracranial primary neoplasm in adults. Over recent years, interest in this clinically diverse group of tumors has intensified, bringing new questions and challenges to the fore, particularly in the fields of epidemiology, radiology, pathology, genetics, and treatment. Interest in modern meningioma research has been stimulated by the high tumor prevalence and the advances in technology. The incidence of meningiomas is climbing, and may indicate increased exposure to environmental risk factors or more sensitive diagnostic modalities. Technological advances have dramatically improved radiologic imaging and radiotherapy treatments, and further refinements are under investigation. Furthermore, the current era of tumor genetics and molecular biology is challenging translational researchers to discover new, targeted, therapeutic agents. This review is an update on the recent advances in the understanding of meningiomas and their management, and highlights pertinent research questions to be addressed in the future.
EPIDEMIOLOGY
In 2005, the incidence of meningiomas in British Columbia, Canada, was 1.81 per 100,000. 1 Meningiomas constituted 16 .96% of all new diagnoses of intracranial neoplasms, in British Columbia. 1 Interestingly, the incidence of meningiomas in British Columbia has trended upwards over the past 20 years (Fig. 1 ). 1 Likewise, this pattern of increasing incidence was also recently noted to have occurred in the United States of America. 2 It is unclear whether this represents a true increase in the development of meningiomas in the North American population, or if the increased incidence of meningioma is due to improved methods of detection. Potential causes of detection bias include the increased availability of magnetic resonance imaging (MRI), leading to greater incidental diagnoses of asymptomatic meningiomas on MRI scans performed for other reasons. A recent publication reports that asymptomatic meningiomas, detected incidentally on MRI, have a prevalence of 1.1% in women and 0.9%. 3 Furthermore, increased longevity of the population may also lead to increased prevalence and incidence; in British Columbia, the peak incidence occurs in the eighth decade ( Fig. 2 ). 1 Overall, meningiomas are more commonly diagnosed in females, occurring at a ratio of 2.09:1. 1 Yet, atypical and anaplastic meningiomas are reported to occur more predominantly in men. 4 The reason for this gender distribution is unclear. It is hypothesized that the hormonal microenvironment may favor meningioma growth in female patients. However, this theory is controversial as there is no difference in sex hormone receptor expression between the sexes to explain the frequency disparity. 5 
RISK FACTORS

Ionising Radiation
The strongest evidence for an environmental risk-factor predisposing to meningioma development is in support of ionizing radiation exposure. Data for atomic bomb survivors demonstrates a significantly elevated incidence of meningiomas, compared with nonexposed population with a relative risk of 6.48. 6 It has been found that increasing time from exposure and increasing radiation dose, are associated with a higher incidence of meningiomas. 6 Therapeutic radiation doses are also associated with increased meningioma risk. Prior therapeutic irradiation of the head (for example, for tinea capitis) has also been associated with increased risk of meningioma. [7] [8] [9] A report from Slovenia published the cumulative actuarial risk of radiation-induced meningiomas in patients who received irradiation during childhood: 0.53% at 10 years, 1.2% at 20 years, followed by a sharp increase to 8.18% at 25 years. 8 Low dose, chronic radiation exposure from cellular phone usage has been hotly debated in the recent literature as a potential risk factor for meningioma tumorigenesis. 10 -18 One case-control study from Sweden suggested an increased risk of benign intracranial tumors in users of cellular phones; for meningioma risk, the odds ratio was 2.1 ͓95% confidence interval (CI) ϭ 1.1-4.3͔ with a latency period of Ͼ10 years. 14 However, when this data was pooled with other case-control studies, no significant trend was found for meningioma risk from cellular or cordless phone usage. 15 Furthermore, 1 meta-analysis from Finland, and additional populationbased, case-control studies from Germany and Sweden, suggest that there is no increased risk of meningioma development from the use of cellular telephones. 16 -18 hypothesized that this is due to the influences of female hormones. Second, men have a higher proportion of malignant meningiomas than women. 19, 20 Third, some meningiomas express estrogen, progesterone and androgen receptors. Fourth, pregnancy has been associated with a protective effect, which increased with the number of pregnancies and age at first pregnancy. 21, 22 And finally, it has been observed that meningiomas tend to have a more rapid growth rate during the later stages of pregnancy. 7, 23 On the other hand, the exact relationship between meningiomas and exogenous hormones remains controversial and unclear. Several retrospective and case-control studies have reported a positive association between the use of hormone replacement therapy and meningioma development. 21,24 -26 Conversely, other studies have found little evidence to support a link between meningioma development and oral contraceptives or hormone replacement therapy. 22, 27, 28 In a population-based case-controlled study, Custer et al 27 reported a statistically non-significant, protective benefit of hormone replacement therapy in women who have been postmenopausal for Ն10 years, this was in contrast to the elevated risk of meningioma in all current, postmenopausal women. The authors hypothesize that the risk of meningioma development may be linked to the changing hormone levels of menopause, rather than the long-term presence or absence of hormone exposure. Furthermore, the limited success of hormonal therapies in the treatment of meningiomas is disappointing. Is the link between meningiomas and hormones only a confounder effect? Further research is required to determine the influence of the hormonal microenvironment on meningioma pathogenesis.
Chemical Exposure
Occupational exposure to lead has been associated with an increased incidence of meningioma. 29 One large, hospital-based, case-control study revealed that occupational lead exposure in individuals with the ALAD2 allele led to a statistically significant increased incidence of meningioma (odds ratio 2.4, 95% CI ϭ 0.7-8.8), which rose with cumulative exposure to lead. 30 The pathway of tumorigenesis is unclear but is thought to be driven by higher blood levels of lead or the mutagenic enzyme ␦-aminolevulinic acid, in carriers of the ALAD2 allele of the ALAD gene. 30 Other chemical exposures may be potential risk factors for meningioma tumorigenesis, however, many of the published studies do not differentiate between the development of meningiomas versus other primary brain tumors. The use of hair dye has been speculated as a potential etiological agent for meningioma development, however, this has not been supported in a case-control study. 31 To our knowledge, there is no published literature on the risk of meningioma development after the administration of systemic or intrathecal chemotherapy.
Infection
Viral infection is a hypothetical etiological agent for meningiomas. A novel, large study from Sweden identified an increasing trend for brain tumor incidence in children with increasing number of younger siblings. 32 In children under 15 years of age, the rate ratio for the incidence of meningioma in patients with 3 or more siblings, compared with patients with no siblings, was 3.71 (95% CI ϭ 1. 88 -7.34) . The authors put forward that a large number of younger siblings increases the likelihood of reinfection by childhood infective agents, thus providing a possible explanation for the observed increased incidence of meningiomas in older children and with increasing number of younger siblings. 1 9 8 6 1 9 8 7 1 9 8 8 1 9 8 9 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 
Family History
There is a familial link for meningioma development: a statistically significant relationship exists between a parental history of meningioma and the risk of meningioma diagnosis (standardized incidence ratio 2.5, 95% CI ϭ 1.3-4.3). 33 The increased incidences of meningiomas in families with neurofibromatosis types 1 and 2 are well reported. These genetic conditions are inherited as autosomal dominant traits of the NF1 locus on chromosome 17 and NF2 locus on chromosome 22, respectively.
CLINICAL FEATURES
Meningiomas may present with focal neurologic symptoms depending on their intracranial location. Seizure activity is one of the more common first presenting symptoms, occurring in 26% of meningioma patients. 3 Raised intracranial pressure is uncommon at presentation, but can occur secondary to obstructive hydrocephalus. Rarely, menigiomas may mimic or present as other medical conditions, including parkinsonism, 34, 35 psychiatric illness, 36 cerebral infarction, 37 and amyotrophic lateral sclerosis. 38 
PATHOLOGY
Sites of Meningiomas
Meningiomas are extra-axial lesions that occur most frequently where arachnoid cells are most numerous, namely within arachnoid villi or granulations where they lie along the dural venous sinuses. 39 Thus, the most common locations include the convexity (parasaggital dura or attached to the saggital sinus), sphenoid ridge and planum sphenoidale. Other locations include the sylvian fissure, parasellar region and olfactory grooves. Meningiomas can arise as intraventricular tumors arising from pia-arachnoid rests, and approximately 10% occur infratentorially including along the tentorial free edge, clivus, foramen magnum, petroclival ligament, and petrous ridge. Infrequently, involvement of the optic nerve sheaths and spinal canal may occur: these locations can lead to diagnostic challenges due to the unusual location.
Grade and Morphology
The most commonly used grading system for meningiomas is that of the World Health Organization (WHO). The WHO classifies meningiomas into 3 grades: benign (WHO grade I), atypical (WHO grade II), and anaplastic or malignant (WHO grade III) 4 ( Fig. 3 ). There is a range of subtypes, based on their histologic appearances, however, the clinical behavior and outcomes correlate with the WHO grade, rather than the histologic subtype. The grading of meningiomas is controversial, and accordingly there is a high incidence of interobserver variability. The common agreement is that most of meningiomas are benign. Atypical and anaplastic (malignant) meningiomas are less frequent: atypical meningiomas constitute 4.7% to 7.2%, whereas anaplastic (malignant) meningiomas comprise 1.0% to 2.8% of all meningioma diagnoses. 4 WHO grade I meningiomas may have a variety of appearances, with the meningothelial, fibroblastic, and transitional variants occurring most commonly. 4 In the meningothelial subtype, lobules of tumor cells are surrounded by thin collagenous septae. Cytologically, the cells resemble normal arachnoid: they are uniform with oval nuclei, and the nuclei may demonstrate central clearing most likely due to glycogenation. The fibroblastic subtype is characterized by spindle-shaped cells resembling normal fibroblasts, with the formation of wide fascicles in an interlacing pattern. (Fig. 3A) The collagenous matrix may vary in quantity. Transitional meningiomas have features that are a mixture of meningothelial and fibroblastic subtypes: the architecture is a mixture of lobular and fascicular Meningioma: Controversies and Challenges elements, often with whorls and psammoma bodies. Other subtypes include psammomatous, angiomatous, secretory, microcystic, lymphoplasmacyte-rich, and metaplastic meningiomas. Clinically, there is no distinction in the behavior or prognostic significance of these numerous benign histological variants. 40 Atypical meningiomas have an increased risk of tumor recurrence, as compared to WHO grade I meningiomas. In the WHO classification, atypical meningiomas are diagnosed based on the increased mitotic index of Ն4 mitoses per 10 high-power fields, or Ն3 of the following features: increased cellularity, small cells with high nuclear:cytoplasmic ratio, prominent nucleoli, uninterrupted patternless or sheet-like growth, and foci of "spontaneous" or "geographic necrosis" 4 ( Fig. 3B ). Of note, the clear cell meningioma variant is an important but rare subgroup of grade II meningiomas, with a deceptively benign histological appearance but an aggressive clinical course. 20 Chordoid meningioma has a histological resemblance to chordoma, and is also considered to be grade II due to its associated increased risk of recurrence. 4 In the current WHO classification, brain invasion is considered a criterion for the designation of grade II. 4 In the past, the presence of brain invasion has been a contentious issue in meningioma grading systems. Traditionally, the presence of brain invasion ( Fig. 4A ) was sufficient for a diagnosis of malignancy. However, retrospective series demonstrated that brain invasion, with benign or atypical histological features, did not have a more sinister behavior than atypical meningiomas without brain invasion. 20, 41 Therefore, it was proposed that brain invasion should also be included as a criterion for atypical meningiomas. 20 This was adopted in the most recent WHO classification published in 2007, a change from the WHO classification published in 2000 which did not formally include brain invasion as an independent diagnostic criterion for either grade II or grade III.
Currently, the WHO criteria for anaplastic/malignant meningiomas are the presence of frankly malignant cytology or Ն20 mitoses per 10 high-power fields 4 (Fig. 3C ). Papillary and rhabdoid meningiomas ( Fig. 4B , C) are rare variants that are also classified as WHO grade III; they typically have an aggressive clinical course with higher rates of recurrence, metastases and mortality. 20 Contrary to older classification systems, extra-cranial metastases are not currently considered a pathological criterion for malignancy. Extracranial metastases are a rare occurrence, and are usually associated with anaplastic histologies. 4
Immunohistochemistry
Hormone receptors are variably expressed, however, one large series demonstrated that 88% of primary meningiomas express progesterone receptors (PR), 40% express estrogen receptors (ER), and 39% express androgen receptors (AR). 5 Compared with the more common benign meningiomas, atypical and anaplastic meningiomas are less likely to express ER or AR. 5 Investigators are currently researching the predictive and prognostic value of the expression of these hormone receptors. In benign meningiomas, PR negativity was recently reported as a statistically significant predictor of recurrence, with ER expression to be of little relevance to local relapse risk. 42 Prognostically, the expression of PR positivity coupled with ER negativity has been found to be favorable for clinical and biologic outcome. 43 However, yet to be clearly determined is the significance of these hormone receptors in tumorigenesis, and also the clinical application of hormone receptor expression to potential treatment options.
Proliferation Index
MIB-1 is an anti-Ki-67 monoclonal antibody that is useful for the analysis of proliferative potentials. The MIB-1 immunohistochemical staining index correlates with the histopathologic grade of meningiomas. Reports demonstrate that the mean MIB-1 staining index is 0.7% to 2.2% for benign meningiomas, 2.1% to 9.3% for atypical meningiomas, and 11.0% to 16.3% for anaplastic meningiomas. 44 Multiply recurrent tumors also have the highest MIB-1 staining index at 8.8%, compared with meningiomas at first recurrence (3.6%) and nonrecurring primary meningiomas (1.6%). 44 
GENETICS
The most consistent genetic abnormality in sporadic meningiomas, and therefore the most studied, involves chromosome 22. The NF2 gene is a tumor suppressor gene located on chromosome 22. Genetic abnormalities of NF2 are present in all grades of meningiomas with matching frequency, and therefore are thought to be an early genetic event in tumorigenesis. 45, 46 Phenotypically, an inherited mutation of the NF2 gene manifests with a high risk of developing meningiomas, as well as other tumors of the central and peripheral nervous system; this genetic disorder is known medically as neurofibromatosis type 2.
In sporadic meningiomas, the NF2 gene may be inactivated by chromosome 22 allelic loss, NF2 gene mutation, or aberrant NF2 promoter methylation. Loss of heterozygosity of chromosome 22 is the most common genetic mutation in sporadic meningiomas, occurring in 47% to 72%. 45, [47] [48] [49] NF2 gene mutation and aberrant NF2 promoter methylation have been found to occur in 24% and 26% of cases, respectively. 48 However, in meningiomas with loss of heterozygosity of chromosome 22, loss of NF2 gene function occurs in only one third of these lesions, thus raising the question of a second tumor suppressor gene located on chromosome 22. 47, 49 New evidence suggests genetic differences between the histologic subtypes of benign meningiomas. In the group of meningiomas with retention of heterozygosity of chromosome 22, 61% were found have meningothelial histology. 49 Recent research has revealed that biallelic inactivation of NF2 is less common in the meningothelial meningioma subtype than the transitional and fibroblastic histologic variants. 49 The authors speculate that biallelic inactivation of the NF2 gene may not be as significant in the tumorigenesis of the meningothelial variant, when compared with the transitional and fibroblastic tumors, and that meningothelial tumors may harbor other mutations in genes that are located outside chromosome 22. 49 This discovery opens up a new area for future research to unearth the genetic karyotypes underlying the various histologic phenotypes of the meningioma group.
Deletion of 1p is the second most common genetic mutation in meningiomas. A recent publication shows 1p to be codeleted with chromosome 22q in 67% of meningiomas. 49 Deletion of 1p is associated with meningioma progression and recurrence. Some investigators have proposed a stepwise progression in malignant transformation by the accumulation of mutations. Deletions of chromosomes 1p, 6q, 10, 14q, and 18q plus chromosomal gains on 1q, 9q, 12q, 15q, 17q, and 20 are associated with increasing grade to atypical meningioma. 50 Further, anaplastic meningiomas are associated with loss of 9p, and 17q amplification. 4, 51 However, yet to be fully determined is the clinical translation of these genetic patterns; in particular, the prognostic outcomes and the potential for targeted therapeutics.
PATHOLOGICAL PREDICTIVE FACTORS FOR RECURRENCE OR PROGRESSION
Currently, histologic grade is the best predictive factor for local recurrence. Atypical and anaplastic/malignant histologies have a greater risk of local recurrence than benign meningiomas. The local failure rate for anaplastic meningiomas is 50% to 94%, atypical meningiomas 29% to 52%, and for benign meningiomas, a 7% to 25% recurrence rate. 4 Furthermore, anaplastic meningiomas are associated with 19% risk of metastatic disease 52 and inferior survival. 4 Additional pathologic features associated with increased recurrence rates include mitotic index Ն20 per 10 high-power fields, loss of chromosome 1p, and Ki-67 labeling index Ͼ12%. 53 Bromodeoxyuridine labeling index represents the proliferative potential of the tumor, and is predictive of recurrence rates. 40, 44 Meningiomas with MIB-1 staining index Ն3% also have a significantly higher risk of recurrence; furthermore, this index has been found to be predictive of recurrence independent of Simpson surgical resection grade. 44 Among atypical and anaplastic meningiomas, Ki-67 labeling index has also been found to be an independent predictor of both tumor recurrence and overall survival. 54
RADIATION-INDUCED MENINGIOMAS
In general, radiation-induced meningiomas have a more biologically aggressive phenotype, and are clinically separate from sporadic meningioma. Atypical or malignant histopathological features ( Fig. 5 ) are present in 24% to 38% of radiation-induced meningiomas, 8, 55 higher than the proportion of higher grade histologies in the sporadic population (Ͻ10%). Radiation-induced meningiomas are associated with a higher risk of local relapse, with a reported relapse rate as high as 100% in one retrospective series. 55 The latency period reported in the literature ranges from 2 to 63 years. 8 Features associated with a shorter latency period include Ͻ5 years of age at time of radiation exposure (16.1 Ϯ 10.3 versus 19.8 Ϯ 9.9 years, P ϭ 0.04) and higher grade (15.8 Ϯ 12.4 vs. 19.1 Ϯ 9.5 years, P ϭ 0.01). 8 Although meningiomas are usually solitary tumors, patients with prior exposure to ionizing radiation have an increased association with multiplicity. 9 Genetically, radiation-induced meningiomas are also a distinct group from sporadic meningiomas. The majority of sporadic meningiomas carry genetic abnormalities involving the NF2 gene, on 22q12.2, and thought to be an early step in tumorigenesis. 45 However, screening for NF2 gene mutations in a population of radiation-induced meningiomas, demonstrates low rates or absence of inactivating mutations in the tumor samples. 45 Loss of heterozygosity of chromosome 22 occurs in 47% to 72% of sporadic meningiomas, however, in radiation-induced meningiomas chromosome 22q allele loss is infrequent, occurring in only 29% of patients. 7, 45 It is, therefore, unlikely that NF2 suppressor gene inactivation is required for radiation-induced meningioma development.
In radiation-induced meningiomas, the most common genetic event is the loss of heterozygosity of chromosome 1p. This occurs in 57% to 89% of radiation-induced meningiomas, a higher frequency than that of sporadic, benign meningiomas, which is approximately 30%. 45 Loss of heterozygosity of 1p has been found to correlate with biologically more aggressive disease in sporadic meningiomas 53 ; it is possible that allelic loss of 1p in radiation-induced meningiomas may explain the more aggressive phenotype of these tumors. 45 
RADIOLOGICAL CHALLENGES
In 80% to 90% of cases, meningiomas have typical imaging appearances in which diagnosis can be made with confidence. The main diagnostic challenges include the distinction from dural metastasis, cerebral lymphoma, hemangiopericytoma, and extra-axial inflammatory conditions (for example, sarcoid); more rarely gliomas and primitive neuroectodermal tumors may masquerade as meningiomas ( Fig. 6 ).
Computed Tomography (CT)
CT provides high spatial resolution imaging and is often the first-line radiologic investigation. Multislice CT scanners are now increasingly available, and allow for superior image reformatting and confirmation of the extra-axial location of meningiomas.
Meningiomas appear as isodense (25%) to slightly hyperdense (70%-75%), sharply circumscribed masses with broad based dural attachments. 56 The majority enhance avidly and homogenously following contrast administration. Cyst formation and calcification are seen in approximately 20%. Ring enhancement is an atypical feature and, coupled with cyst formation, can give an appearance that mimics a malignant, intra-axial neoplasm.
Hyperostosis, which may resemble Paget disease or fibrous dysplasia, is seen in 20% 40% of meningiomas on CT. 57, 58 The hyperostosis is usually benign, occurring as a result of dural-induced hypervascularity causing reactive thickening of the adjacent periosteum. However, hyperostosis may also represent bone invasion, and distinguishing between the two pathologic processes can be difficult on imaging (Fig. 7) . On the otherhand, calvarial invasion may manifest with radiologic appearances of destruction and lysis. The identification of bone invasion is important as it influences treatment decisions. Bone invasion is often thought to indicate aggressive tumor behavior; however, this finding does not always correlate with the histologic morphology.
Hemangiopericytoma is often confused with malignant meningioma, however, the former is associated with a more aggressive clinical course, and, therefore, the diagnostic distinction is of clinical importance. Important features that are suggestive of hemangiopericytoma over meningioma include absence of calcification, lack of hyperostosis, bone destruction, and lobulated contour.
Magnetic Resonance Imaging (MRI)
With superior image resolution and multiplanar capabilities, MRI allows for better delineation of the dural extent and extra-axial location of tumors. Argument exists as to whether MRI or CT is more sensitive, however, in clinical practice, correlation of both modalities aids diagnosis. In British Columbia, a CT of the brain is a more economical preliminary investigation for patients presenting with neurologic symptoms.
Meningiomas appear isointense or slightly hypointense to cortex on T1-weighted imaging, and variably isointense to hyperintense on T2-weighted imaging reflecting the amount of tumor calcification, necrosis, vascularity, and cell type. 57, 58 Gadolinium administration results in strong, homogenous tumor enhancement and provides superior lesion conspicuity (Fig. 8 ). This is particularly valuable for the purposes of determining the tumor margins for the accurate planning of stereotactic radiotherapy.
Diagnostic clues to the presence of meningioma seen on MRI include cortical buckling, peritumoral edema, and a "dural tail," best appreciated following the administration of gadolinium. The dural tail sign occurs in 35% to 80%, and although not pathognomonic, it is perhaps the best diagnostic sign. The dural tail represents reactive dural thickening and edema as a consequence of tumor tracking along the meninges. Identification of anatomic interfaces between the tumor and brain surface also aids diagnosis. These anatomic interfaces include pial vascular structures, hypointense dura, and cerebrospinal fluid clefts. [57] [58] [59] The latter is best visualized on fine slice T2 weighted image when the cerebrospinal fluid clefts have high intensity.
Magnetic Resonance Venography (MRV) and Magnetic Resonance Spectroscopy (MRS)
Radiologic characterization of meningiomas has been advanced by MRV and MRS. Contrast-enhanced MRV provides reliable information on the extent of venous infiltration and collateral venous anastomoses, which is of surgical relevance. Biochemical data can be obtained noninvasively by MRS: a characteristic alanine peak for meningioma is 1.3 to 1.5 ppm. 56, 58 Majos et al 60 identified 2 groups in which MRS could be of particular assistance: first, tumors that do not have a classic appearance on imaging, and second, tumors resembling intra-axial neoplasms on imaging. In this study, diagnosis was improved by an alanine peak at 1.47 ppm or high relative concentrations of choline and glutamine/glutamate, and low concentrations of creatine-containing compounds, N-acetylcontaining compounds and lipids. 60
Angiography
Characteristically, angiography reveals a spoke wheel pattern of vessels, indicating slow growth. The classic "mother in law blush" persists from the capillary phase into the venous phase, and when present, this appearance is almost pathognomonic. In 85% of meningiomas, the blood supply is derived from the external carotid artery, and microcatheterization via the external carotid artery to vessels supplying the meningioma can allow for therapeutic embo- 
Meningioma Variants and Atypical Features
Meningioma variants are notoriously difficult to distinguish using traditional imaging modalities. However, a review of 40 cases of biopsy-proven meningioma demonstrated a correlation between MRI T2-weighted appearance and histopathology in Ͼ75% of cases: fibroblastic or transitional elements were present in markedly hypointense lesions, and angioblastic or syncytial elements in markedly hyperintense lesions. 62 The lipoblastic and sclerotic subtypes are 2 rare variants that can cause diagnostic confusion. The lipoblastic meningioma develops as a result of metaplasia into adipocytes; therefore it has a low density or Hounsfield number on CT, and is T1 hyperintense on MRI. The sclerotic subtype may show poor or partial enhancement, and is often calcified.
RADIOLOGICAL FINDINGS THAT PREDICT CLINICAL BEHAVIOR
Malignant subtypes have an increased mitotic index and greater cellularity than benign variants. This hypercellularity may have effects on diffusivity in diffusion weighted MRI, with more cellular lesions displaying restricted diffusion. Atypical and anaplastic meningiomas have a lower average diffusion constant than benign meningiomas. 63 However, benign meningiomas can have a variable appearance on diffusion-weighted MRI which may be misleading; in particular, densely calcified or psammomatous meningiomas may have a lower average diffusion constant than other benign histologies. 63 Calcification is a predictor of the growth rate of meningiomas. A retrospective study of the radiologic doubling-time of meningiomas revealed that calcified meningiomas on CT had a lower annual growth rate than noncalcified lesions. 64 An inverse relationship between calcification and growth has been reported, using the MIB-1 staining index obtained from surgical specimens. 65 MIB-1 staining of excised tumors from a series of 342 consecutive patients identified the imaging features of nonskull base location and absence of calcification, as independent risk factors for high proliferative potential. 66 Cerebral edema may also indicate more aggressive clinical behavior. Edema can develop secondary to compressive ischemia, venous stasis, parasitisation of pial arteries, or direct brain infiltration. One study of 55 meningioma patients confirmed a statistically significant correlation between the WHO grade and the degree of peritumoural edema on CT and MRI (P ϭ 0.0089). 67 Reports have also found that severe edema is associated with more aggressive syncytial and angioblastic cell types, and mild to moderate edema associated with fibroblastic and transitional cell types. 62, 68 Conversely, other studies have not supported this finding. 69
Positron Emission Tomography (PET)
Positron emission tomography with radio-labeled F-fluorodeoxyglucose has been shown to be useful in predicting behavior and recurrence. 70 Benign meningiomas exhibit hypometabolic uptake relative to the cortex, compared to atypical and malignant types which have higher glucose utilization. 56, 71 Interestingly, a high glucose metabolism is also seen in radiation-induced meningiomas. 56
New Technologies
New research tools using perfusion and diffusion tensor imaging (DTI) are providing information with regards to occult invasion in normal appearing white matter. In a study by Provenzale et al, 72 DTI using fractional anisotropy measurements was used in regions of normal appearing white matter and peritumoural hyperintense regions in patients with high grade gliomas and benign meningiomas; in the high grade glioma group, evidence of possible tumor infiltration in normal appearing white matter was detected by the reduction in fractional anisotropy. The authors concluded that DTI may help to detect tumor infiltration that is not visible on standard MRI imaging. A potential future application of this technology may be the detection of occult brain infiltration by invasive meningiomas, although this hypothesis is yet to be proven.
THERAPEUTIC CHALLENGES Surgery
Although the majority of meningiomas are benign, their natural history risks devastating neurologic deficit and morbidity if left untreated. Therefore, therapeutic intervention is mandated for most diagnosed tumors. In current clinical practice, surgery is the treatment of choice for meningiomas. Surgical removal allows for histologic diagnosis, relieves mass effect and associated symptoms, alleviates tumor-induced seizures, and achieves high local control rates. Modern neurosurgical technology, intraoperative monitoring, and skull-base approaches allow the majority of meningiomas to be removed safely and completely.
Not all tumors can be fully resected without considerable morbidity. Safe and complete surgical resection is precluded by the encasement of critical intracranial nerves and arteries, or venous sinus invasion. Resectability also depends on the site of the tumor due to the impact on surgical access. Typical locations where total meningioma removal is difficult include the cavernous sinus, clivus, cerebellopontine angle, and sellar region. Modern neurosurgical techniques aim to reduce the rate of surgical morbidity, and in challenging sites, subtotal resection is often preferred over radical, gross total resection. 73 For these situations, where complete and safe removal is precluded, an effective strategy is that of subtotal resection followed by postoperative radiotherapy. Follow-up, serial imaging is mandatory for all cases with incomplete resection or aggressive histologic grade.
For benign menigiomas, extent of resection is a major clinical predictor for recurrence. A retrospective series from M.D. Anderson Cancer Center demonstrated a significant reduction in the 10 year progression-free survival in patients with incompletely excised, benign meningiomas: from 61% following gross total resection, to 37% for incompletely excised tumors. 74 The Simpson Classification of surgical resection correlates with local recurrence rates (Table 1) . 40, 75 Developed in 1957, this classification system has withstood the test of time and remains well used in modern clinical practice.
There are several other predictors for meningioma recurrence. A recent retrospective study of 137 patients investigated preopera- tive risk factors for relapse: multivariate analysis revealed mushroom shape, osteolysis and location within 1 cm of a major sinus to be independent, significant negative predictors for time to recurrence. 75 On univariate analysis, additional risk factors included tumor size Ͼ4 cm, severe edema, cortical penetration and intensity on T2-weighted MRI, pial-artery supply on angiography, intermediate or invasive brain-tumor interface, Simpson grade, and histologic appearance of higher grade tumor. In the presence of these risk factors, the authors recommend a wider dural removal and close radiologic observation in the follow-up period.
Although meningiomas have an excellent prognosis overall, mortality rates are poorly reported. From the time of first surgical resection, the 5 year progression-free and overall survival rates for benign meningiomas are in the order of 65% and 93%, respectively. 74 At 10 years, these figures decline to 49% and 85%, respectively. 74 Anaplastic meningiomas, however, have a worse prognosis with median survival less than 2 years. 4
Definitive Radiotherapy
Definitive radiotherapy achieves a high rate of long-term tumor control, however, clinical practice favors radical surgery as the gold standard for resectable meningiomas as it avoids the morbidity of radiation-induced toxicities. Definitive radiotherapy is usually reserved for patients with unresectable meningiomas or contraindications to surgery. One large, retrospective series compared the radiographic local control rates from definitive stereotactic radiosurgery (SRS) versus surgical resection of benign meningiomas, Յ35 mm in diameter. 76 The progression-free survival rate following definitive SRS was equivalent to that obtained by Simpson grade I resection (95% and 96% at 7 years, respectively), and superior to the progression-free survival rates following grade II or grade III to IV resections (82% and 34% at 7 years, respectively). The authors conclude that definitive SRS is an acceptable alternative for meningiomas that cannot be safely removed with a Simpson grade 1 resection.
Postoperative Radiotherapy
Postoperative radiotherapy is the accepted standard of care for patients with atypical and anaplastic meningiomas, to optimize local control and improve survival. 52 Increasing doses of postoperative radiotherapy are associated with improved local control, 52 however, at the cost of an increased risk of radiationinduced toxicity.
On the otherhand, postoperative radiotherapy for benign histologies is more controversial. Randomized data on the outcomes of postoperative radiotherapy for meningiomas is lacking, and retrospective reports do not conclusively demonstrate a long-term survival benefit. 74 However, the limited available evidence suggests that the addition of postoperative radiotherapy improves local control in the subset of patients with subtotal resection. The investigators at M.D. Anderson Cancer Center reported a strongly significant increase in the 5 year progression-free survival rate from the addition of postoperative stereotactic radiotherapy: 91% versus 38% in patients treated without postoperative radiotherapy for subtotally resected, benign meningiomas (P ϭ 0.0005). 74 However, 5 year overall survival was 90% in both groups. Therefore, in current clinical practice, postoperative radiotherapy is often considered for incompletely resected, benign meningiomas (Simpson grade III-V) to reduce local recurrence risk.
However, the timing of radiotherapy remains contentious: postoperative radiotherapy versus salvage radiotherapy at the time of tumor progression. The impact of postoperative radiotherapy on neuro-cognitive function and quality of life, versus the impact by tumor recurrence and salvage treatment, is unclear. The phase III EORTC-26021 study, from European Organisation for Research and Treatment of Cancer, was designed to address these unanswered questions by randomizing incompletely excised, benign meningiomas to postoperative radiotherapy or observation. 77, 78 However, this study failed to achieve accrual targets and was closed early, leaving the dilemma unresolved. Other considerations in this debate include the small risk of late, radiation-induced carcinogenesis, and the uncertainty if postoperative radiotherapy impacts upon the rate of malignant transformation in benign meningiomas.
Modern Radiotherapy Techniques
Modern radiotherapy techniques include stereotactic radiosurgery, stereotactic radiotherapy, and intensity modulated radiotherapy. These techniques aim to improve the therapeutic ratio by minimizing the dose to critical structures. The modern radiotherapy planning process is aided by MRI and CT fusion, which improves tumor delineation through the complementary detail of soft tissue extension and bony erosion, respectively. 79 The optimal radiotherapy dose is unclear. With the exception of one retrospective study published over a decade ago, 80 there is a paucity of evidence regarding the dose response of meningiomas to radiotherapy. This is an area that deserves future investigation, to optimize the therapeutic ratio of tumor control versus normal tissue toxicity.
Stereotactic Radiosurgery (SRS)
SRS involves rigid immobilization of the patient and stereotactic localization of the tumor, to deliver a single fraction of radiation to the tumor within 1 mm accuracy, with steep dose gradients to protect nearby normal tissues. Single doses of 13 to 20 Gy to the tumor margin are standard. 81, 82 There are several factors that make SRS attractive. First, the radiobiology of slow growing meningiomas, with low ␣/␤ ratio, favors high dose-per-fraction for increased tumor cell kill. Second, the rapid dose drop-off allows for sparing of the adjacent normal tissues. Third, the convenience of a single fraction is very appealing for both patients and for radiation oncology departments with long waiting lists. However, not all meningiomas are amenable to this treatment modality. The limitations include: (1) difficulty delivering full radiation dose to the dural tail of the meningioma, (2) unsuitability of meningiomas Ͼ35 mm in diameter, and (3) the risk of radiation-induced toxicity to adjacent dose-limiting structures with low ␣/␤ ratios, which are sensitive to hypofractionated radiotherapy.
Stereotactic Fractionated Radiotherapy (SFRT)
Stereotactic radiotherapy involves the delivery of a fully fractionated course of radiotherapy using a relocatable stabilization device. Dedicated planning systems incorporate multiple radiotherapy beams to improve the conformality of the radiotherapy dosimetry plan to the planning target volume ( Fig. 9 ). Like SRS, the planning and delivery of SFRT shares the same principles of stereotaxis and stabilization, however, SFRT has the added advantage of sparing the critical normal tissues that are sensitive to hypofractionation (for example, optic chiasm, brain stem, and cranial nerves). Therefore, SFRT is the preferred treatment for optic nerve sheath meningiomas 83 and other tumors that are not amenable to SRS due to proximity to critical structures.
Intensity Modulated Radiotherapy (IMRT)
IMRT uses inverse-planning with multiple modulated beams to obtain dose homogeneity through the planning target volume, plus sharp dose gradients to spare nearby dose-limiting structures to within pre-determined dose constraints. Therefore, IMRT is particularly advantageous for the treatment of tumors that are irregularly shaped, close to critical normal tissues, or too large for stereotactic radiotherapy. A radiotherapy planning study of skull-base meningi-American Journal of Clinical Oncology • Volume 32, Number 1, February 2009 Meningioma: Controversies and Challenges omas, found that stereotactic IMRT produced consistently higher conformality index and sparing of dose-limiting structures than stereotactic radiotherapy, with the greatest benefit seen in multifocal and irregular tumors. 84 However, the volume of normal tissue receiving low radiation dose was greater in patients treated with IMRT 84 ; this finding is worth noting only with respect to the as-yet unproven hypothesis that this higher integral dose may be associated with increased risk of radiation-induced neoplasms. 85
Systemic Therapies
There is very little role for systemic therapies in routine management of meningiomas. Benign meningiomas have excellent local control rates and survival following local therapies, such that the potential benefit from an adjuvant systemic agent is likely to be very small. Furthermore, the toxicity of the systemic agent can undermine the therapeutic ratio.
The greatest benefit from systemic therapies may occur in refractory or high grade meningiomas, as local control and survival rates are disappointing with current therapeutic techniques. To date, chemotherapy and hormonal therapies have shown little benefit in atypical and anaplastic meningiomas. 59 There are few randomized trials. Small phase II studies have demonstrated very modest efficacy, if any, from chemotherapy agents, including temozolamide, 60 hydroxyurea, 61, 62 and irinotecan. 63 Hormonal therapies have also shown little success in the management of meningioma. One phase III trial of 193 patients with unresectable, non-malignant meningiomas were randomized to receive antiprogestin or placebo, no difference in response or freedom from progression was found. 64 Tamoxifen has also been investigated but without significant clinical benefit. 65 Immunomodulatory interferon ␣-2b is reported to have some cytostatic activity in meningiomas, 66, 67 however, the data is scant and no recommendations for its use can be made at this time. Somatostatin has been studied in vitro and in vivo, on the basis that somatostatin receptors are present on most meningiomas. 86 A prospective trial of sustained release somatostatin in 16 patients with recurrent meningioma, demonstrated a radiographic, partial response rate of 31% with minimal toxicity. 86 FIGURE 9. A 3-dimensional, conformal, stereotactic radiotherapy plan to treat a meningioma of the optic nerve sheath, using Brain-Laboratory stereotactic radiotherapy planning system.
Targeted Therapies
Molecular-based, targeted therapies may hold more promise than conventional chemotherapy. Meningiomas are vascular tumors, so a block in the molecular pathway for angiogenesis may inhibit further tumor growth. Vascular endothelial growth factor (VEGF), and its receptor, are expressed in meningiomas, and are involved in angiogenesis. VEGF expression is increased in atypical and anaplastic histologies, compared with benign meningiomas. 87 Anti-VEGF agents may be effective in control of tumor growth in these histologies. Meningiomas express also platelet-derived growth factor (PDGF) subunits and receptors, which play a role in cell proliferation. PDGF-BB and activated PDGF-͓beta͔-receptor are over-expressed, particularly in atypical and anaplastic meningiomas. 87 Therefore, PDGF inhibitors may have a role in the targeted management of in these histologies. At present, targeted therapy for meningiomas remain investigational.
Neuro-Cognitive Outcomes and Quality of Life
Neuro-cognition and quality of life outcomes are important considerations. Treatment can alleviate neurologic symptoms caused by the meningioma, however, this may be at the cost of neuro-toxicity.
Late side effects of radiotherapy are permanent and potentially serious, and therefore represent dose-limiting considerations. The risk depends on the radiation dose received by the radiosensitive tissue and the irradiated volume, and increases over time. These toxicities include cataract formation, optic neuropathy, neurosensory hearing loss, hypopituitarism, deterioration in neuro-cognition, cerebral necrosis, and carcinogenesis. Fortunately, the reported incidence of severe radiation-induced toxicities is low, although there is a paucity of published data with prospectively collected, long-term follow-up. One large retrospective study from Heidelberg, Germany, reported on the late side effects of SFRT in 189 meningioma patients. The incidence of grade III late toxicity after SFRT was 2.1%, however, the incidence of new grade III toxicity in patients without that pre-existing complaint was 1.5%. No patients experienced grade IV toxicity. 88 Radiotherapy is more often associated with an improvement in symptomatic neuro-cognitive dysfunction, however, there is a small but definite risk of subsequent decline. The Heidelberg investigators found that 87.5% of patients have neurologic deficits before radiotherapy; neurologic deficits which did not interfere with daily life (grade I) were present in 50.6% of patients, moderate deficits (grade II) were present in 27.8%, and 9% had serious neurologic deficits (grade III). 88 After completing radiotherapy, 44.8% of these patients had an improvement in at least 1 neurologic symptom, whereas only 9% had symptomatic progression of a pre-existing neurologic problem.
Neurologic effects of surgery are greatest in the immediate postoperative period. One cohort study of patients with brain invasion meningiomas found that the rate of neurologic deterioration 7 days after surgery was 25%, however, by 3 months, the majority had improved and the proportion of patients with neurologic deterioration fell to 7.5%. 89 This incidence of neurologic deficits was found to be positively correlated with both tumor location in an eloquent area and the extent of peritumoural edema. 89 Recent retrospective evidence suggests that there is no deterioration from the addition of postoperative radiotherapy, in terms of neuro-cognition and quality of life. van Nieuwenhuizen et al 90 reported on the neuro-cognitive functioning and quality of life of grade I meningioma patients 1 year after treatment, in a matched cohort study comparing the outcomes of surgery alone, surgery plus postoperative radiotherapy and a group of healthy controls. No significant difference was found in the neuro-cognitive function of patients treated with surgery alone versus surgery plus postoperative radiotherapy. However, all meningioma patients had lower neurocognitive function compared with the healthy controls, with the most profound effect occurring in memory tasks. Health-related quality of life was inferior in the group treated with surgery and postoperative radiotherapy, however, this observed difference was lost when taking into account the time from diagnosis, suggesting that the impairment in quality of life was more likely attributable to the longer disease history rather than the radiotherapy treatment. 90
The Challenges of Treating Elderly Patients
As previously discussed, modern imaging modalities can provide radiologic clues to meningioma grade and behavior. This finding may help guide prognostication, presurgical planning and influence treatment decisions in elderly or frail patients.
In elderly patients with asymptomatic meningiomas, "close observation" is a valid approach to avoid the morbidity associated with surgery or radiotherapy. One large retrospective series of 348 surgically-managed meningioma patients demonstrated higher incidences of neurologic deterioration and surgical complications in patients aged 65 and older: with the incidence of postoperative hematoma, infection, and deep venous thrombosis reaching statistical significance. 91 However, the potential disadvantage of close observation is the risk of symptom development associated with tumor progression, and the subsequent impact on quality of life. Therefore, follow-up with serial imaging is recommended for these patients, so that treatment can be instigated before clinically significant neurologic deficits arise. This group of patients would benefit from improved predictive and prognostic determinants, to more definitively distinguish between those who will or will not benefit from active treatment. Molecular-based targeted therapies that are less invasive and less toxic than conventional treatments are also likely to be of benefit to improve the therapeutic ratio in this medically vulnerable group.
CONCLUSIONS
The study of meningiomas is an exciting and expanding field for epidemiological, clinical, translational, and basic science researchers. Based on the high frequency of these tumors, the earlier paucity of research and the modern advances in technology, it is currently a "boom time" for meningioma research. The biologic understanding and medical management of these tumors is likely to be revolutionized in the not-so-distant future. A team approach, linking laboratory-based research and multidisciplinary clinical practice, will be an essential element to lead meningioma management forward and beyond 2008.
